RxDoctor Payments Data

Elena Weinstein, MD

Rheumatology · Aurora, CONPI 1962474882

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Argenx US, Inc. accounts for 90.8% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for rheumatology clinicians in CO, where the typical reported total is $1,681.

$270in general payments, 2019–2025

Across 5 payments — averaging $53.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Argenx US, Inc.$245
  • Amgen$25
$290,601in research payments, 2019–2025

Across 17 payments — averaging $17,094 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$144K
  • Novartis$106K
  • AbbVie$41K

What the payments were for

  • Food & beverage$270100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Argenx US, Inc.4$245
Amgen1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$270 in reported general payments places this provider in the 35th percentile of 108 rheumatology providers in Colorado.

See all rheumatology providers in Colorado

Medicare billing

Part B allowed, 2024
$37,518
Medicare patients
181
Services billed
523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XeljanzTofacitinib Citrate38$221,536
Humira(Cf) PenAdalimumab15$216,775
Humira PenAdalimumab23$188,867
Cosentyx Sensoready (2 Pens)Secukinumab23$155,324
OrenciaAbatacept25$148,988
Enbrel SureclickEtanercept20$147,156
Taltz AutoinjectorIxekizumab16$112,624
Xeljanz XrTofacitinib Citrate12$64,316
BenlystaBelimumab13$61,200
OtezlaApremilast13$59,715
Teriparatide25$58,294
Hydroxychloroquine Sulfate147$9,877
MethotrexateMethotrexate Sodium188$5,492
Pilocarpine Hcl23$2,970
Celecoxib39$2,374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$25$59,71513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 108 rheumatology providers in Colorado.

Other rheumatology in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →